BigCommerce Transforms Commerce Beyond Order Capture with Pipe17 Partnership
AUSTIN, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands, retailers, manufacturers and distributors today announced a transformational partnership with Pipe17, a leading provider of AI-powered composable order operations. This partnership reimagines how modern merchants manage orders in an increasingly complex digital commerce ecosystem.
BigCommerce empowers brands, retailers, manufacturers and distributors of all sizes to sell online and capture orders seamlessly. Feedonomics, BigCommerce's AI-powered product data feed management and order orchestration solution, helps brands list, manage and optimize product, inventory, pricing and order data across third-party channels, from ads, to social commerce, to marketplaces. The next frontier of commerce lies in the back office—turning captured orders into packages on consumers' doorsteps or trucks on businesses' loading docks.
Today's customers expect to shop anywhere—through merchant-owned channels like their brand websites and mobile apps, marketplaces like Amazon and Walmart, social platforms like TikTok and Instagram, and increasingly AI agents. They also demand instant delivery and flawless order fulfillment, pushing brands to expand their fulfillment infrastructure with additional warehouses, third-party logistics (3PL) partnerships, generous returns policies and new technology.
As selling channels proliferate and fulfillment infrastructure grows in both size and complexity, problems rapidly shift to the back office—specifically order management. Merchants struggle to route orders and ensure order-related data is perfectly synchronized between selling channels, 3PLs, warehouse management systems (WMSs), customer service and back-office systems of record such as an ERP, and any one of dozens or hundreds of systems that touch order and order-adjacent data.
Pipe17's order operations network transforms the way orders, inventory and data flow through the modern commerce landscape. Unlike outdated and monolithic order management systems (OMSs) that attempt to be the center of every integration, Pipe17 is built atop an AI-powered network composed of hundreds of endpoints. In partnership with BigCommerce, this dynamic, scalable, and composable approach gives merchants unmatched flexibility and control of their connectivity, product listings, order routing and order-related data flows.
With this partnership, merchants on the BigCommerce platform, as well as Feedonomics customers on any platform, can leverage Pipe17's connectivity network to extend their coverage across critical fulfillment endpoints.
'Order Management is ripe for disruption, and Pipe17 delivers a game-changing solution with its innovative order operations platform,' said Travis Hess, CEO of BigCommerce. 'BigCommerce has always made it easy for merchants to capture orders, and Feedonomics helps merchants sell everywhere their customers shop, and by partnering with Pipe17, we can now ensure those orders from both owned channels and third-party channels move smoothly through our customers' fulfillment infrastructure and back-office setup, ensuring a seamless flow through the delivery process.'
'Commerce is all about delivering great customer experiences,' said Mo Afshar, CEO of Pipe17. 'We're proud to partner with BigCommerce to help merchants unify their commerce operations and stay ahead of the evolving digital commerce landscape. Together, with BigCommerce's world-class API-first open commerce platform, product data management and order capture solutions and Pipe17's order operations network that delivers the order management capabilities merchants need without the bloated OMS they despise, we're enabling sellers to create better, more intelligent and further reaching customer experiences.'
"We saw during the height of the Covid pandemic, and beyond, the importance of accurately managing orders and fulfillment across multiple sales channels,' said James Grandefeld, Chief Operating Officer at Bona Fide Masks, 'Our partnership with both of these great platforms lets us provide best in class service to our valued customers. We are excited about the partnership and what it means for us.'
To learn more about BigCommerce's partnership with Pipe17, visit the company's booth (#1944) at Shoptalk, March 25-27, 2025.
About BigCommerceBigCommerce (Nasdaq: BIGC) is a leading open SaaS and composable ecommerce platform that empowers brands, retailers, manufacturers and distributors of all sizes to build, innovate and grow their businesses online. BigCommerce provides its customers sophisticated professional-grade functionality, customization and performance with simplicity and ease-of-use. Tens of thousands of B2C and B2B companies across 150 countries and numerous industries rely on BigCommerce, including Coldwater Creek, Harvey Nichols, King Arthur Baking Co., MKM Building Supplies, United Aqua Group and Uplift Desk. For more information, please visit www.bigcommerce.com or follow us on X and LinkedIn.
About FeedonomicsFeedonomics is the leading data management platform powering omnichannel growth for the world's top brands and retailers. With its flexible technology and full-service support team, Feedonomics facilitates a variety of data and order management use cases across industries such as ecommerce, automotive, employment, travel, real estate, and more. Feedonomics has thousands of active customers, integrations with hundreds of ecommerce platforms and channels, and strategic partnerships with industry leaders like Amazon, Meta, Google, Microsoft and TikTok. To learn more about Feedonomics, a platform-agnostic BigCommerce subsidiary, visit www.feedonomics.com. For more information, please visit www.feedonomics.com or follow us on Twitter, LinkedIn, Instagram and Facebook.
About Pipe17Pipe17 Inc. provides AI-Powered Order Operations solutions for modern merchants and fulfillment service providers. Based in Seattle, Pipe17 is the fastest and easiest way to make omnichannel order flows touchless and cost-efficient, from order to inventory to fulfillment across DTC, B2B, and Retail. Pipe17 is the only ecommerce order operations solution that combines rapid deployment, seamless orders-to-anywhere automation, real-time visibility, and elastic scale. Learn more at https://Pipe17.com or follow us on LinkedIn.
Media contacts:For BigCommerce and FeedonomicsBrad Hempr@bigcommerce.com
For Pipe17,Jon Gettingerjon.gettinger@pipe17.comSign in to access your portfolio
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
27 minutes ago
- Associated Press
Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY
- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY® - - Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world - TORONTO, July 3, 2025 /CNW/ - Vertex Pharmaceuticals (Nasdaq: VRTX) recently announced positive longer-term data for PrCASGEVY® (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress, continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy. 'This longer-term data reinforces CASGEVY's durable clinical benefits for eligible people living with sickle cell disease or transfusion-dependent beta thalassemia,' said Kevin Kuo, M.D., Hematologist and Associate Professor in the Division of Hematology, University of Toronto, Clinician Investigator in the Red Blood Cell Disorders Clinic at University Health Network, and Principal Investigator for the CLIMB-131 clinical program. 'These results are a reminder of what science can achieve, especially for patients and communities with significant unmet need.' New longer-term follow-up data presented from the CASGEVY trials Progress in bringing CASGEVY to patients Through reimbursement agreements, Vertex has secured access for eligible SCD or TDT patients in multiple countries including Austria, Bahrain, England, Denmark, the Kingdom of Saudi Arabia, Northern Ireland, Scotland, the United Arab Emirates, the United States and Wales. In Canada, CASGEVY received positive recommendations for reimbursement from both Canadian health technology agencies between December 2024 and January 2025; however, a Letter of Engagement from the pan-Canadian Pharmaceutical Alliance (pCPA) is pending. Vertex is continuing to work with government and reimbursement authorities globally to secure sustainable access for additional eligible patients. About Sickle Cell Disease (SCD) SCD is a debilitating, progressive, life-shortening genetic disease. SCD patients report health-related quality of life scores well below the general population and significant health care resource utilization. SCD affects the red blood cells, which are essential for carrying oxygen to all organs and tissues of the body. SCD causes severe pain, organ damage and shortened life span due to misshapen or 'sickled' red blood cells. The clinical hallmark of SCD is vaso-occlusive crises (VOCs), which are caused by blockages of blood vessels by sickled red blood cells and result in severe and debilitating pain that can happen anywhere in the body at any time. SCD requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About Transfusion-Dependent Beta Thalassemia (TDT) TDT is a serious, life-threatening genetic disease. TDT patients report health-related quality of life scores below the general population and significant health care resource utilization. TDT requires frequent blood transfusions and iron chelation therapy throughout a person's life. Due to anemia, patients living with TDT may experience fatigue and shortness of breath, and infants may develop failure to thrive, jaundice and feeding problems. Complications of TDT can also include an enlarged spleen, liver and/or heart, misshapen bones and delayed puberty. TDT requires lifelong treatment and significant use of health care resources, and ultimately results in reduced life expectancy, decreased quality of life and reduced lifetime earnings and productivity. About PrCASGEVY® (exagamglogene autotemcel) PrCASGEVY® is an autologous genome edited hematopoietic stem cell-based therapy for eligible patients with SCD or TDT, in which a patient's own hematopoietic stem and progenitor cells are edited at the erythroid specific enhancer region of the BCL11A gene through a precise double-strand break. This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is the form of the oxygen-carrying hemoglobin that is naturally present during fetal development, which then switches to the adult form of hemoglobin after birth. CASGEVY has been shown to reduce or eliminate vaso-occlusive crises (VOCs) for patients with SCD and transfusion requirements for patients with TDT. CASGEVY is approved for eligible SCD and TDT patients 12 years and older by multiple regulatory bodies around the world. About the CLIMB Trials The ongoing Phase 1/2/3 open-label trials, CLIMB-111 and CLIMB-121, are designed to assess the safety and efficacy of a single dose of CASGEVY in patients ages 12 to 35 years with TDT or with SCD and recurrent VOCs. The trials are closed for enrollment. Patients will be followed for approximately two years after CASGEVY infusion in these trials. Each patient will be asked to participate in the ongoing long-term, open-label trial, CLIMB-131. CLIMB-131 is designed to evaluate the long-term safety and efficacy of CASGEVY in patients who received CASGEVY, including those in other CLIMB trials. The trial is designed to follow patients for up to 15 years after CASGEVY infusion. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies in select regions for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 15 consecutive years on Science magazine's Top Employers list and one of Fortune's 100 Best Companies to Work For. For company updates and to learn more about Vertex's history of innovation, visit Vertex Special Note Regarding Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, the statements by Kevin Kuo, M.D., in this press release, and statements regarding expectations for the anticipated durable clinical benefits of CASGEVY, expectations for the safety profile of CASGEVY, expectations for the Letter of Engagement from the pCPA, plans to continue working with government and reimbursement authorities globally to secure sustainable access for patients, and our plans for and design of the CLIMB studies. While we believe the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that eligible patient access to CASGEVY may not be achieved on the anticipated timeline, or at all, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy, and other reasons, and other risks listed under the heading 'Risk Factors' in Vertex's most recent annual report and subsequent quarterly reports filed with the Securities and Exchange Commission at and available through the company's website at You should not place undue reliance on these statements, or the scientific data presented. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. Vertex Pharmaceuticals Incorporated Investors: [email protected] Media: Canada: +1 647-790-1600 or U.S.: 617-341-6992 SOURCE Vertex Pharmaceuticals (Canada) Inc.
Yahoo
27 minutes ago
- Yahoo
Smithfield Foods (SFD) Is Quietly Crushing It with Strong EBITDA and Room to Grow
Smithfield Foods Inc. (NASDAQ:SFD) is one of the 20 undervalued momentum stocks that are taking off. Smithfield Foods presents a compelling investment opportunity, backed by strong fundamentals, resilient profitability, and a clear path for growth. With $14.1 billion in FY 2024 sales and $1.4 billion in adjusted EBITDA, Smithfield has established itself as a leading U.S. food company, anchored by its high-margin packaged meats segment. Packaged meats now account for 59% of Smithfield's total revenue, with $8.3 billion in sales and a 13.6% adjusted operating margin. The company has outperformed its peers in profitability, supported by its brand strength, product diversification, and broad reach in retail and foodservice. Smithfield holds the No. 2 branded market share across 25 key meat categories and reaches 93% of all commodity volume (ACV) across retailers. It also serves all of the top 10 grocery/club stores and 70% of leading foodservice chains. A busy supermarket with shelves full of packaged foods. On the operational side, Smithfield's vertically integrated model enables it to ensure supply chain stability and cost control. The company is also optimizing its hog production operations, reducing commodity exposure while securing raw material needs for its packaged meats and fresh pork segments. Smithfield's 2025 guidance calls for continued profit growth and investments in automation, innovation, and premium offerings. With a strong balance sheet, including $3.2 billion in liquidity and a low 0.7x net debt-to-EBITDA ratio as of March 2025, the company is well-positioned to invest in strategic M&A and deliver shareholder returns, including a planned annual dividend of $1.00 per share. Smithfield Foods Inc. (NASDAQ:SFD) is an American food company and an industry leader in value-added packaged meats and fresh pork. While we acknowledge the potential of SFD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 10 Best Tech Stocks to Buy According to Billionaires. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Lyft (LYFT) Upgraded to Buy, Crowned TD Cowen's Top SMID-Cap Pick
Lyft Inc. (NASDAQ:LYFT) is one of the 20 undervalued momentum stocks that are taking off. On June 24, TD Cowen analyst John Blackledge upgraded Lyft Inc. to Buy from Hold, raising the price target from $16 to $21. Notably, he named Lyft his 'Best SMID-cap Idea' (small and mid-cap stock idea) for 2025. Blackledge pointed to several key factors behind his upgraded view. One of the main reasons was Lyft's focus on smaller U.S. markets. As per the analyst, cities such as Charlotte and Indianapolis showed over 30% year-over-year growth in Q1 2025, suggesting strength outside the company's traditional top-tier markets. A close-up view of a hand holding a smartphone, using a ride sharing app. International expansion was another reason. The analyst highlighted Lyft's planned acquisition of FREENOW, a European mobility platform, which is expected to contribute roughly €1 billion in annual gross bookings. Growth in Canada has also been notable, up 100% in 2024 and continuing with 50% growth in Q1 2025. The analyst also highlighted that product innovation and improved user experience are also supporting the company's growth. Blackledge pointed to initiatives such as Price Lock, which allows users to lock specific fares while helping Lyft build a base of recurring subscription revenue. The recent partnership with DoorDash is also driving user engagement and expanding the active rider base. Blackledge believes Lyft is executing well and doesn't need to gain market share from Uber, as it currently holds about 30% of the U.S. rideshare market, for its stock to perform. Over the long term, he sees upside from autonomous vehicles, which should expand the overall market opportunity. Lyft Inc. (NASDAQ:LYFT) is a leading ride-sharing and mobility-as-a-service company that connects passengers with drivers through its digital platform. The company operates in major cities across the U.S. and Canada, offering ride-hailing, bike and scooter rentals, and fleet management solutions. While we acknowledge the potential of LYFT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and 10 Best Tech Stocks to Buy According to Billionaires. Disclosure: None.
